Classical and Emerging Biomarkers in Pyridoxine-Dependent Epilepsy (PDE-ALDH7A1): Implications for Early Diagnosis
Muna Abedrabbo1, Safiya Al Yazeedi2, Blair R Leavitt1,3
1Centre for Molecular Medicine and Therapeutics, BC Children's Hospital and the Department of Medical Genetics, University of British Columbia, 950 West 28th Avenue, Vancouver, BC V5Z 4H4, Canada.
Insights
Pyridoxine-dependent epilepsy (PDE-ALDH7A1) stems from impaired lysine breakdown, causing neurodevelopmental issues. New, stable biomarkers offer improved diagnostics and potential for better treatments beyond pyridoxine.
Area of Science:
- Biochemistry
- Genetics
- Neurology
Background:
- Pyridoxine-dependent epilepsy due to ALDH7A1 deficiency (PDE-ALDH7A1) is a rare epileptic encephalopathy.
- It results from disrupted lysine catabolism, leading to pyridoxal-5'-phosphate (PLP) depletion.
- Current treatments with pyridoxine control seizures but not neurodevelopmental impairment.
Purpose of the Study:
- To review lysine catabolism in health and disease.
- To evaluate diagnostic biomarkers for PDE-ALDH7A1.
- To discuss novel biomarkers for improved diagnosis and understanding of disease mechanisms.
Main Methods:
- Literature review of lysine catabolism and PDE-ALDH7A1.
- Critical evaluation of existing biomarkers (α-AASA, P6C, pipecolic acid).
- Highlighting novel biomarkers (6-oxo-PIP, 2-OPP, HACA) identified via metabolomics.
Main Results:
- Classical biomarkers (α-AASA, P6C, pipecolic acid) are unstable and challenging for diagnostics.
- Novel, stable biomarkers (6-oxo-PIP, 2-OPP, HACA) show promise for newborn screening.
- These new biomarkers offer mechanistic insights into seizure susceptibility and neurological morbidity.
Conclusions:
- Advances in biomarker discovery are revolutionizing PDE-ALDH7A1 diagnostics.
- Novel biomarkers facilitate earlier detection and understanding of disease pathophysiology.
- This paves the way for developing more effective, mechanism-based therapies for PDE-ALDH7A1.
Abstract:
Pyridoxine-dependent epilepsy due to ALDH7A1 deficiency (PDE-ALDH7A1) is a rare but treatable epileptic encephalopathy caused by disruption of lysine catabolism and secondary depletion of pyridoxal-5'-phosphate (PLP). Although seizures are often controlled with pyridoxine supplementation, many patients continue to experience neurodevelopmental impairment, underscoring the importance of early diagnosis and improved therapeutic strategies. Central to both diagnosis and pathophysiology is the accumulation of lysine-derived metabolites, most notably α-aminoadipate semialdehyde (α-AASA), its cyclic Schiff base Δ1-piperideine-6-carboxylate (P6C), and pipecolic acid. These metabolites have become the biochemical hallmarks of PDE-ALDH7A1, linking ALDH7A1 pathogenic variants to PLP inactivation and neuronal dysfunction. However, their chemical instability and analytical requirements pose challenges for universal diagnostics and newborn screening. This review summarizes current understanding of lysine catabolism in health and disease, critically evaluates the diagnostic utility and limitations of classical biomarkers, and discusses emerging insights into their pathophysiological roles. We further highlight recent discoveries of novel, chemically stable biomarkers, including 6-oxopiperidine-2-carboxylic acid (6-oxo-PIP), 2-oxopropylpiperidine-2-carboxylic acid (2-OPP), and 6-hydroxy-2-aminocaproic acid (HACA), identified through advanced metabolomics approaches. These metabolites show promise for newborn screening and provide new mechanistic links between metabolic stress, seizure susceptibility, and ongoing neurological morbidity despite pyridoxine treatment. Collectively, advances in biomarker discovery are reshaping diagnostic strategies for PDE-ALDH7A1 and offering new perspectives on disease mechanisms, paving the way for earlier detection and the development of more effective, mechanism-based therapies.
More Related Videos
11:03Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
Published on: February 10, 2020
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
